Literature DB >> 21197369

Stochastic Approximation and Modern Model-based Designs for Dose-Finding Clinical Trials.

Ying Kuen Cheung1.   

Abstract

In 1951 Robbins and Monro published the seminal paper on stochastic approximation and made a specific reference to its application to the "estimation of a quantal using response, non-response data". Since the 1990s, statistical methodology for dose-finding studies has grown into an active area of research. The dose-finding problem is at its core a percentile estimation problem and is in line with what the Robbins-Monro method sets out to solve. In this light, it is quite surprising that the dose-finding literature has developed rather independently of the older stochastic approximation literature. The fact that stochastic approximation has seldom been used in actual clinical studies stands in stark contrast with its constant application in engineering and finance. In this article, I explore similarities and differences between the dose-finding and the stochastic approximation literatures. This review also sheds light on the present and future relevance of stochastic approximation to dose-finding clinical trials. Such connections will in turn steer dose-finding methodology on a rigorous course and extend its ability to handle increasingly complex clinical situations.

Entities:  

Year:  2010        PMID: 21197369      PMCID: PMC3010381          DOI: 10.1214/10-STS334

Source DB:  PubMed          Journal:  Stat Sci        ISSN: 0883-4237            Impact factor:   2.901


  24 in total

1.  On the use of nonparametric curves in phase I trials with low toxicity tolerance.

Authors:  Ying Kuen Cheung
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  Bayesian optimal designs for Phase I clinical trials.

Authors:  Linda M Haines; Inna Perevozskaya; William F Rosenberger
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

Review 3.  Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study.

Authors:  J O'Quigley; S Chevret
Journal:  Stat Med       Date:  1991-11       Impact factor: 2.373

4.  A curve-free method for phase I clinical trials.

Authors:  M Gasparini; J Eisele
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

5.  A random walk rule for phase I clinical trials.

Authors:  S D Durham; N Flournoy; W F Rosenberger
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

6.  Design and analysis of phase I clinical trials.

Authors:  B E Storer
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

Review 7.  Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.

Authors:  M J Ratain; R Mick; R L Schilsky; M Siegler
Journal:  J Natl Cancer Inst       Date:  1993-10-20       Impact factor: 13.506

8.  Design of phase I and II clinical trials in cancer: a statistician's view.

Authors:  N L Geller
Journal:  Cancer Invest       Date:  1984       Impact factor: 2.176

9.  Cancer phase I clinical trials: efficient dose escalation with overdose control.

Authors:  J Babb; A Rogatko; S Zacks
Journal:  Stat Med       Date:  1998-05-30       Impact factor: 2.373

10.  Bayesian decision procedures for dose determining experiments.

Authors:  J Whitehead; H Brunier
Journal:  Stat Med       Date:  1995 May 15-30       Impact factor: 2.373

View more
  5 in total

Review 1.  Efficiency perspectives on adaptive designs in stroke clinical trials.

Authors:  Ken Cheung; Petra Kaufmann
Journal:  Stroke       Date:  2011-09-01       Impact factor: 7.914

Review 2.  Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.

Authors:  Mei-Yin C Polley; Ying Kuen Cheung
Journal:  JCO Precis Oncol       Date:  2019-10-24

3.  On the efficiency of nonparametric variance estimation in sequential dose-finding.

Authors:  Chih-Chi Hu; Ying Kuen Cheung
Journal:  J Stat Plan Inference       Date:  2013-03       Impact factor: 1.111

4.  Simple benchmark for complex dose finding studies.

Authors:  Ying Kuen Cheung
Journal:  Biometrics       Date:  2014-02-25       Impact factor: 2.571

5.  A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation.

Authors:  Jin Xu; Dapeng Zhang; Rongji Mu
Journal:  BMC Med Res Methodol       Date:  2022-10-01       Impact factor: 4.612

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.